EP 1159286 A4 20030115 - TUMOR NECROSIS FACTOR RECEPTORS 6 ALPHA AND 6 BETA
Title (en)
TUMOR NECROSIS FACTOR RECEPTORS 6 ALPHA AND 6 BETA
Title (de)
TUMORNEKROSEFAKTOR-REZEPTOREN 6 ALPHA UND 6 BETA
Title (fr)
RECEPTEURS DU FACTEUR DE NECROSE TUMORALE 6 ALPHA ET 6 BETA
Publication
Application
Priority
- US 0005686 W 20000303
- US 12177499 P 19990304
- US 12409299 P 19990312
- US 13127999 P 19990427
- US 13196499 P 19990430
- US 14637199 P 19990802
- US 16823599 P 19991201
Abstract (en)
[origin: WO0052028A1] The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6 alpha and -6 beta proteins. TNFR-6 alpha and -6 beta polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6 alpha and -6 beta activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
IPC 1-7
C07K 14/00; C12P 21/00; C12N 5/00; C12N 5/06; C12N 15/63; C12Q 1/68
IPC 8 full level
C12N 15/09 (2006.01); A61K 35/76 (2006.01); A61K 38/00 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61P 1/00 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 3/10 (2006.01); A61P 5/14 (2006.01); A61P 7/06 (2006.01); A61P 9/00 (2006.01); A61P 9/02 (2006.01); A61P 9/04 (2006.01); A61P 9/06 (2006.01); A61P 9/08 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 9/14 (2006.01); A61P 13/12 (2006.01); A61P 19/08 (2006.01); A61P 19/10 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 31/18 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); A61P 43/00 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12P 21/02 (2006.01); C12R 1/91 (2006.01)
CPC (source: EP KR)
A61P 1/00 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 1/16 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 5/14 (2017.12 - EP); A61P 7/06 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/02 (2017.12 - EP); A61P 9/04 (2017.12 - EP); A61P 9/06 (2017.12 - EP); A61P 9/08 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 9/14 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 19/08 (2017.12 - EP); A61P 19/10 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/04 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07K 14/7151 (2013.01 - EP KR); C12N 15/63 (2013.01 - KR); C12P 21/00 (2013.01 - KR); A61K 38/00 (2013.01 - EP)
Citation (search report)
- [X] WO 9904001 A1 19990128 - ZYMOGENETICS INC [US]
- [X] WO 9907738 A2 19990218 - REGENERON PHARMA [US], et al
- [PX] WO 9946376 A1 19990916 - BASF AG [DE], et al
- [PX] WO 9914330 A1 19990325 - GENENTECH INC [US]
- [PX] WO 9926977 A1 19990603 - BIOGEN INC [US], et al
- See references of WO 0052028A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0052028 A1 20000908; AU 3723400 A 20000921; AU 774845 B2 20040708; CA 2362929 A1 20000908; CN 1345329 A 20020417; EP 1159286 A1 20011205; EP 1159286 A4 20030115; HK 1042498 A1 20020816; JP 2003512020 A 20030402; KR 20020013506 A 20020220; MX PA01008936 A 20030721; NZ 513294 A 20040430
DOCDB simple family (application)
US 0005686 W 20000303; AU 3723400 A 20000303; CA 2362929 A 20000303; CN 00804601 A 20000303; EP 00916071 A 20000303; HK 02104273 A 20020605; JP 2000602253 A 20000303; KR 20017011253 A 20010904; MX PA01008936 A 20000303; NZ 51329400 A 20000303